Search

Close
Research
Home > Research > Faculty
Research

HE Aina  

  • Chief Physician, Doctoral Supervisor
  • Department: Oncology
  • Research Area: Oncology
  • Research Interests: High-throughput drug screening based on tumor organoids Research on the immune microenvironment based on tumor organoids
  • Contact: anna_1188@126.com
Biography Positions Publications Research Projects Patents
  • PhD in Internal Medicine, Zhejiang University, 2009
  • Bachelor’s Degree in Clinical Medicine, Zhejiang University, 2004
  • Postdoctoral Fellow, Department of Urology, Boston Children’s Hospital, Harvard University, 2019
  • Postdoctoral Fellow, Department of Genetics, Brigham and Women’s Hospital, Harvard University, 2017
  • Chief Physician, Department of Medical Oncology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 2022–Present
  • Associate Chief Physician, Department of Medical Oncology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 2015–2022
  • Attending Physician, Department of Medical Oncology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 2011–2014
  • Physician, Department of Medical Oncology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 2009–2010
  • Director (Discipline Leader), Department of Oncology, Shanghai Sixth People’s Hospital (South Campus)
  • Standing Committee Member, Translational Medicine Branch, China Gerontological and Geriatrics Society
  • Secretary, Committee of Precision Oncology, Shanghai Medical Doctor Association
  • Young Committee Member, Oncology Subspecialty Society, Shanghai Medical Association
  • Committee Member, Committee of Cancer Immunotherapy and Translational Medicine, Shanghai Research-Based Hospitals Society
  • Committee Member, Committee of Rehabilitation and Palliative Care, Shanghai Anti-Cancer Association
  • Committee Member, Medical-Engineering Alliance, Chinese Journal of Tissue Engineering Research
  • Industry Mentor (Professional Degree Postgraduates), Lanzhou University
  • Secretary-General, Organoid Committee, Shanghai Anti-Cancer Association
  • Master’s Supervisor, Southern Medical University
  • Deputy Director, Organoid Research Center, Jiaxing, Zhejiang Province
  • Vice Chair, Committee of Organoid Technology and Clinical Translation, Shanghai Health Promotion Association
  1. Li J, Zhang L, He A#. Tumor-derived CCL5 recruits CCR1+ macrophages to suppress apoptosis and drive proliferation in duodenal adenocarcinoma. Cancer Letters, 2025, doi: 10.1016/j.canlet.2025.218064.
  2. Ma L, Pang Z, He A#. Clear cell renal carcinoma essentially requires CDKL3 for oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2025, doi: 10.1073/pnas.2415244122.
  3. Liang Y, Li Z, He A#. Adipocytes Promote Cisplatin Resistance through Secreting A1BG and Regulating NAMPT/PARP1 Axis-Mediated DNA Repair in Osteosarcoma. Advanced Science, 2025, doi: 10.1002/advs.202502926.
  4. Xiang D, He A, Liu Y. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics, 2024, doi: 10.7150/thno.96027.
  5. Huang Y, Cao D, He A#. Exploring the impact of PDGFD in osteosarcoma metastasis through single-cell sequencing analysis. Cellular Oncology, 2024, doi: 10.1007/s13402-024-00949-3.
  6. He A, Tian S, Kopper O. Targeted inhibition of Wnt signaling with a Clostridioides difficile toxin B fragment suppresses breast cancer tumor growth. PLOS Biology, 2023, doi: 10.1371/journal.pbio.3002353.
  7. Wang Z, Zhao S, He A#. Application of organoids in carcinogenesis modeling and tumor vaccination. Frontiers in Oncology, 2022, doi: 10.3389/fonc.2022.855996.
  8. Chen G, Gong T, He A#. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution. Cellular Oncology, 2022, doi: 10.1007/s13402-022-00705-5.
  9. Zhou C, Wu Y, He A#. Standardization of organoid culture in cancer research. Cancer Medicine, 2023, doi: 10.1002/cam4.5943.
  10. He A#, Huang Y, Chen W. Organoid culture system for patient-derived lung metastatic osteosarcoma. Medical Oncology, 2020, doi: 10.1007/s12032-020-01429-y.
  • 01/01/2025-12/31/2027
    Shanghai Municipal Health Commission, ¥200,000, 2024ZZ2032
    Organoid-based differentiation of benign versus malignant serous cavity effusions and effective drug screening
    Role: Topic manager
  • 01/01/2022-12/31/2024
    National Natural Science Foundation of China (General Program), ¥550,000, 82173358
    Mechanistic study of the novel Wnt pathway inhibitor TcdB-FBD in suppressing triple-negative breast cancer growth via regulation of cancer stem cells
    Role: Topic manager
  • 10/01/2021-10/31/2024
    Shanghai Sixth People’s Hospital (General Incubation Program), ¥300,000, ynms202112
    Role and mechanisms of neutrophils in p53-deficient breast cancer initiation
    Role: Topic manager
  • 07/01/2018-06/30/2021
    St. Baldrick’s Foundation International Scholar Award (USA), ¥2,000,000, 585350
    Treating gastric sarcoma: biobank establishment and application of Wnt inhibitors
    Role: Topic manager
  • 07/01/2016-06/30/2019
    Shanghai Natural Science Foundation, ¥200,000, 16ZR1425900
    Correlation of CDKL3 with gastric sarcoma tumorigenesis and progression and mechanistic investigation
    Role: Topic manager
  • 01/01/2011-12/31/2013
    National Natural Science Foundation of China (Young Scientists Fund), ¥200,000, 81001191
    Role and mechanisms of CD133-positive gastric sarcoma cell subclones in pulmonary metastasis
    Role: Topic manager
  • 07/01/2010-06/30/2012
    Shanghai Pujiang Talent Program, ¥200,000, 10PJ1408300
    Identification of metastatic gastric sarcoma stem cells and underlying mechanisms
  • Role: Topic manager
  1. [Gengming Niu, Aina He, Tianyi Tang, Siyu Luan] (2023), “Drug Sensitivity Testing Method for Bone Tumor Organoids”, CN202311698874.4.
  2. [Aina He, Gengming Niu, Heming Xu] (2024), “Pharmaceutical Composition for Treating Tumor and Application Thereof”, CN202411155358.1.
  3. [Gengming Niu, Aina He, Guiying Wei, Yue Yang, Xue Zhang] (2024), “Method for Detecting the Expression Level of a Drug Target”, CN202311827003.8.
  4. [Dongxi Xiang, Jiaoduan Li, Xiuying Xiao, Aina He] (2024), “Application of a Targeted Inhibitor in the Treatment and/or Prevention of Duodenal Cancer”, CN202311357962.8.
  5. [Dongxi Xiang, Jiaoduan Li, Aina He, Lixin Jiang] (2024), “Targeted Inhibitor Capable of Effectively Inhibiting Organ Metastasis of BAP1-Inactivated Mutant Uveal Melanoma”, CN202310685260.6.

Copyright © 2024, All Rights Reserved.